Macrophage-targeted chitosan anchored PLGA nanoparticles bearing doxorubicin and amphotericin B against visceral leishmaniasis
- 28 July 2016
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (75) , 71705-71718
Abstract
Novel chitosan-coated nanoparticles with a high payload of amphotericin B (AmB) and doxorubicin (Dox) were formulated employing a nanoprecipitation technique and evaluated for antileishmanial activity against Leishmania donovani. FTIR, DSC and TG-DTA analysis ensured the physicochemical compatibility of drugs and polymers. The chitosan-coated optimized nanoparticle formulation resulted in a mean particle size; 374.4 ± 4.8 nm, PDI; 0.227 ± 0.035 and zeta potential; (+) 32.9 ± 1.10 mV. The entrapment efficiency was determined to be 70.2 ± 4.76 and 93.86 ± 2.61% for AmB and Dox respectively. An in vitro drug release study demonstrated the release of 27.29 and 36.93% AmB and Dox, respectively after 24 h from chitosan-coated PLGA nanoparticles which is slower than the release obtained from uncoated PLGA nanoparticles of AmB and Dox (32.82 and 57.93% AmB and Dox respectively after 24 h). Stability studies confirmed no remarkable alterations in the physicochemical properties of nanoparticles. Cs-PLGA-ABDx was less hemotoxic (22.87 ± 0.487%) than PLGA-ABDx (36.71 ± 2.08%) and the ABDx suspension (97.04 ± 5.01%) at 42.78 μg mL−1 AmB and 80 μg mL−1 Dox. Cell uptake investigation showed the mean florescence intensity of chitosan-coated PLGA-FITC was 2.02 fold higher than uncoated PLGA-FITC nanoparticles. The cytotoxicity in J774A.1 cells revealed Cs-PLGA-ABDx was less cytotoxic compared to the ABDx suspension and PLGA-ABDx, whereas the IC50 of Cs-PLGA-ABDx against infected macrophages was significantly (p < 0.05) lower than PLGA-ABDx indicating the effectiveness of Cs-PLGA-ABDx. No significant increase in the biomedical markers AST, BUN and PC was observed in Cs-PLGA-ABDx treated groups at 1 and 3 mg kg−1 dose. These experimental findings put forward Cs-PLGA-ABDx to be a suitable alternative in the management of visceral leishmaniasis.Keywords
Funding Information
- Central Drug Research Institute (HOPE)
This publication has 44 references indexed in Scilit:
- Chitosan-Modified PLGA Nanoparticles with Versatile Surface for Improved Drug DeliveryAAPS PharmSciTech, 2013
- Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasisJournal of Antimicrobial Chemotherapy, 2012
- Severity of doxorubicin‐induced small intestinal mucositis is regulated by the TLR‐2 and TLR‐9 pathwaysThe Journal of Pathology, 2011
- Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery CarrierPolymers, 2011
- Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasisJournal of Microencapsulation, 2011
- Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug deliveryNanomedicine: Nanotechnology, Biology and Medicine, 2010
- Alkaloids: Future prospective to combat leishmaniasisFitoterapia, 2009
- Thermoanalytical study of praziquantel-loaded PLGA nanoparticlesRevista Brasileira de Ciências Farmacêuticas, 2006
- Targeting of Parasite‐Specific Immunoliposome‐Encapsulated Doxorubicin in the Treatment of Experimental Visceral LeishmaniasisThe Journal of Infectious Diseases, 2004
- Synergistic Effect of Interferon‐γ and Mannosylated Liposome‐Incorporated Doxorubicin in the Therapy of Experimental Visceral LeishmaniasisThe Journal of Infectious Diseases, 1999